Companies /Healthcare

Caris Life Sciences

NASDAQ: CAI Biotechnology
$32.00
▲ $0.29 (+0.91%) today
Markets closed · 2:07pm ET

CAI at a Glance

Valuation
Market cap
$9.0B
P/E ratio
18.9
Profitability
Revenue (TTM)
$989.6M
Profit margin
10.6%
EPS (TTM)
$1.69
Price
52-week range
$14 – $33
Street target
$32.08
Earnings
Next report
Nov 4, 2026

Headquartered in Irving, TX Fiscal year ends December NASDAQ: CAI carislifesciences.com

About Caris Life Sciences

Caris Life Sciences is a TechBio company that develops and commercializes precision medicine solutions for oncology. The company's core platform combines comprehensive molecular profiling — including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing — with advanced AI and machine learning to analyze the molecular complexity of cancer. Through its large-scale, multimodal clinico-genomic database of over 1.13 million patient profiles, Caris offers products spanning therapy selection (MI Profile), minimal residual disease monitoring (Caris Assure), multi-cancer early detection (Caris Detect), and genomic profiling for hematologic malignancies (ChromoSeq). The company also operates pharma research and development services that leverage its database and analytical capabilities to support drug development. Caris serves oncologists, health systems, and pharmaceutical companies through direct commercial operations in the U.S. and distributor partnerships internationally. Updated

CAI Coverage

Frequently Asked Questions

What does Caris Life Sciences do?

Caris Life Sciences is a TechBio company that develops and commercializes precision medicine solutions for oncology.

What is the CAI stock price target?

The Wall Street consensus 12-month price target for CAI is $32.08.